Business Wire

JT-GROUP

14.12.2022 07:02:43 CET | Business Wire | Press release

Share
JT Group Recognized on CDP’s “Climate Change A List” for the 4th Consecutive Year

Japan Tobacco Inc. (JT) (TSE: 2914) has once again been recognized for its leadership in corporate sustainability by the global environmental non-profit organization CDP. JT achieved a place on CDP's prestigious "A List"1 for tackling climate change for the fourth consecutive year.

JT is one of 283 companies in the world and 74 companies in Japan that were included on the "Climate Change A List", out of more than 15,000 companies participating in the CDP environmental disclosure program in 2022. This marks JT's fifth recognition for climate change following 2016, 2019, 2020 and 2021.

In 2019, the JT Group launched the “JT Group Environment Plan 2030”, reflecting changes in its business environment, with energy and emissions, natural resources and waste as key focus areas. Specific examples of measures the Group is taking to reduce its contribution to climate change, include the introduction of renewable energy and the reduction of greenhouse gas emissions from business activities as well as from the raw materials and services it purchases.

Hisato Imokawa, Senior Vice President, Chief Sustainability Officer, said:
"We are honored that JT has been included on the CDP’s 'Climate Change A List' for the fourth consecutive year. This inclusion reflects our continued efforts to reduce our environmental footprint and expand our transparency in disclosing information. As a leading international company, we believe that addressing global environmental concerns, especially those relating to climate change, forms the basis of our business management.
In February 2022, we updated our targets for ’Energy and Emissions’ in the ‘JT Group Environment Plan 2030’, aiming to achieve carbon neutrality by 2030 and Net-Zero greenhouse gas emissions across our entire value chain by 2050. 
The JT Group will continue to contribute to the sustainable development of society by further fulfilling our responsibility to the environment and maintaining the trust of our stakeholders.”
JT Group’s 2030 Greenhouse Gas (GHG) reduction targets in relation to Scope 1, 2 and 3 emissions have been deemed to be in conformance with the criteria set by the Science Based Targets Initiative (SBTi).

Society’s interest in ESG and its demands on companies are increasing year by year, and it is essential for companies to work on improving their sustainability initiatives, to ensure continuous growth. In light of this, the JT Group has placed sustainability at the forefront of its management agenda, and our employees are working hand-in-hand to address ESG issues. To ensure that a healthy and sustainable environment is passed on to future generations, the JT Group is committed to achieving a balance between corporate activities and environment preservation by addressing environmental challenges in wider society as well as in the Group’s value chain.

About CDP
CDP (HQ: London) is the leading international non-profit organization that accelerates action to achieve sustainable economies, assessing disclosure and actions by companies from around the world. Representing over 680 investors with assets of USD 131 trillion, CDP sends out questionnaires to companies listed on stock exchanges worldwide, asking them about their activities for reducing greenhouse gas emissions and safeguarding water resources, then evaluates the answers and publishes the scores.

1 CDP scores companies from D- to A based on their environmental performance, which starts with disclosure, and progresses to awareness, management, and finally to leadership. CDP's A List recognizes the world's companies leading on environmental performance.

###

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries and regions. With approximately 55,000 employees, it manufactures and sells some of the world’s best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under its Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit https://www.jt.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005606/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye